Could a diabetes pill stop liver damage in hepatitis b?
NCT ID NCT05147090
First seen Jan 30, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study tests whether empagliflozin, a diabetes drug, can prevent liver scarring (fibrosis) from getting worse in people with chronic hepatitis B. About 106 adults with moderate to severe liver scarring will take either the drug or a placebo daily for three years. The goal is to see if the drug slows or stops liver damage, even in patients without diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Hong Kong/Queen Mary Hospital
Hong Kong, Hong Kong, China, 852, Hong Kong
Conditions
Explore the condition pages connected to this study.